SCHEMBL2160010

SCHEMBL2160010

COc1cccc(OC(=O)Oc2cccc(OC)c2OC)c1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 3/20 0.56
KDM4E B2RXH2 2/20 0.50
HPGD P15428 2/20 0.50
LMNA P02545 1/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50
CA14 Q9ULX7 1/20 0.50
HSD17B10 Q99714 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
TSHR P16473 1/20 0.46
CYP1A1 P04798 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
ALOX5 P09917 1/20 0.45
TRPM8 Q7Z2W7 1/20 0.45
MAPT P10636 1/20 0.45
PRMT1 Q99873 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29286402 0.87 NFE2L2 (0.49) NFE2L2KDM4EHPGDLMNACA12
SCHEMBL1954243 0.87 CA12 (0.54) NFE2L2KDM4EHPGDLMNACA12
SCHEMBL2160012 0.86 NFE2L2 (0.54) NFE2L2KDM4EHPGDLMNACA12
SCHEMBL6963260 0.86 NFE2L2 (0.54) NFE2L2KDM4EHPGDLMNACA12
SCHEMBL3327023 0.86 MAPK1 (0.58) NFE2L2KDM4EHPGDLMNACA12
SCHEMBL3624482 0.84 NFE2L2 (0.53) NFE2L2KDM4EHPGDLMNACA12
SCHEMBL25304559 0.83 NFE2L2 (0.53) NFE2L2KDM4EHPGDLMNACA12
SCHEMBL29286399 0.82 NFE2L2 (0.49) NFE2L2KDM4EHPGDLMNACYP1A1
SCHEMBL25434306 0.82 CA1 (0.61) NFE2L2KDM4EHPGDLMNACA12
SCHEMBL151213 0.82 CA1 (0.61) NFE2L2KDM4EHPGDLMNACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5527875-A Process for producing aromatic polycarbonate MITSUBISHI CHEMICAL CORPORATION (JP) 1996-06-18 US claimed
US-10377847-B2 Strong reversible hydrogels SUPRAPOLIX B.V. (NL) 2019-08-13 US disclosed
EP-2343342-B1 STRONG REVERSIBLE HYDROGELS SUPRAPOLIX BV (NL) 2015-09-16 EP disclosed
US-20140128482-A1 STRONG REVERSIBLE HYDROGELS SUPRAPOLIX B.V. (NL) 2014-05-08 US disclosed
US-8628789-B2 Strong reversible hydrogels SUPRAPOLIX, B.V. (NL) 2014-01-14 US disclosed
EP-2343342-A1 Strong reversible hydrogels SupraPolix B.V. (NL) 2011-07-13 EP disclosed
EP-1972661-B1 Strong reversible hydrogels SUPRAPOLIX BV (NL) 2011-07-06 EP disclosed
US-20080260795-A1 STRONG REVERSIBLE HYDROGELS SUPRAPOLIX B.V. 2008-10-23 US disclosed
EP-1972661-A1 Strong reversible hydrogels SupraPolix B.V. (NL) 2008-09-24 EP disclosed
EP-0703262-B1 Process for producing aromatic polycarbonate MITSUBISHI CHEM CORP (JP) 1999-12-15 EP disclosed
EP-0673959-B1 Process for producing aromatic polycarbonate MITSUBISHI CHEM CORP (JP) 1998-10-28 EP disclosed
US-5578694-A MELT POLYCONDENSATION OF AROMATIC DIOL AND DIARYL CARBONATE; ESTER INTERCHANGE USING PHOSPHONIUM CATALYST MITSUBISHI CHEMICAL CORPORATION (JP) 1996-11-26 US disclosed
US-5527875-A Process for producing aromatic polycarbonate MITSUBISHI CHEMICAL CORPORATION (JP) 1996-06-18 US disclosed
EP-0703262-A2 Process for producing aromatic polycarbonate Mitsubishi Chemical Corporation (JP) 1996-03-27 EP disclosed
EP-0673959-A1 Process for producing aromatic polycarbonate Mitsubishi Chemical Corporation (JP) 1995-09-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10377847-B2 Strong reversible hydrogels HSPA4L, H1-4, CD44 NFE2L2 3034/4885KDM4E 934/4885HPGD 185/4885
US-20080260795-A1 STRONG REVERSIBLE HYDROGELS HSPA4L, H1-4, CD44 NFE2L2 3034/4885KDM4E 934/4885HPGD 185/4885
US-20140128482-A1 STRONG REVERSIBLE HYDROGELS HSPA4L, H1-4, CD44 NFE2L2 3034/4885KDM4E 934/4885HPGD 185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.